A Phase 4, Randomized, Double-Blind, Multicenter, Parallel Group, Active-Controlled, Dose-Optimization Safety and Efficacy Study of SPD489 (Vyvanse) Compared with OROS-MPH (Concerta) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Atten